Can-Fite Signed Recently An Agreement With Fondazione Telethon For The Co-development Of Piclidenoson For Lowe Syndrome In Japan
Portfolio Pulse from Benzinga Newsdesk
Can-Fite BioPharma has signed an agreement with Fondazione Telethon for the co-development of Piclidenoson for Lowe Syndrome in Japan. Additional meetings with Japanese companies interested in Can-Fite's oncology and dermatology indications are also planned.
October 09, 2023 | 11:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Can-Fite's new partnership and potential expansion into the Japanese market could positively impact its stock in the short term.
The news of Can-Fite's partnership with Fondazione Telethon for the co-development of a drug for Lowe Syndrome, along with potential interest from other Japanese companies, could be seen as a positive development by investors. This could lead to increased demand for Can-Fite's stock, potentially driving its price up in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100